Nxera Pharma Co., Ltd. - Laporan Laba Rugi (TTM)

Nxera Pharma Co., Ltd.
US ˙ OTCPK ˙ JP3431300007

Laporan Laba Rugi (TTM)

Laporan Laba Rugi Nxera Pharma Co., Ltd. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 6,399 8,842 8,887 9,449 7,989 17,712 17,624 17,046 22,763 15,569 15,393 15,258 12,402 12,766 16,434 23,340 29,275 28,835 30,868 31,209
Change (%) 38.18 0.51 6.32 -15.45 121.70 -0.50 -3.28 33.54 -31.60 -1.13 -0.88 -18.72 2.94 28.73 42.02 25.43 -1.50 7.05 1.10
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 777 761 812 875 868 933 995 1,017 1,035 926 730 620 1,538 3,102 4,201 6,369 5,427 7,616 8,040 7,597
Change (%) -2.06 6.70 7.76 -0.80 7.49 6.65 2.21 1.77 -10.53 -21.17 -15.07 148.06 101.69 35.43 51.61 -14.79 40.34 5.57 -5.51
% of Revenue 12.14 8.61 9.14 9.26 10.86 5.27 5.65 5.97 4.55 5.95 4.74 4.06 12.40 24.30 25.56 27.29 18.54 26.41 26.05 24.34
Gross Operating Profit 5,622 8,081 8,075 8,574 7,121 16,779 16,629 16,029 21,728 14,643 14,663 14,638 10,864 9,664 12,233 16,971 23,848 21,219 22,828 23,612
Change (%) 43.74 -0.07 6.18 -16.95 135.63 -0.89 -3.61 35.55 -32.61 0.14 -0.17 -25.78 -11.05 26.58 38.73 40.52 -11.02 7.58 3.43
% of Revenue 87.86 91.39 90.86 90.74 89.14 94.73 94.35 94.03 95.45 94.05 95.26 95.94 87.60 75.70 74.44 72.71 81.46 73.59 73.95 75.66
SG&A 2,374 2,525 2,717 2,798 2,938 3,138 3,517 3,469 3,420 3,535 3,290 3,841 6,377 8,167 10,708 13,618 14,407 12,924 16,066 12,468
Change (%) 6.36 7.60 2.98 5.00 6.81 12.08 -1.36 -1.41 3.36 -6.93 16.75 66.02 28.07 31.11 27.18 5.79 -10.29 24.31 -22.40
% of Revenue 37.10 28.56 30.57 29.61 36.78 17.72 19.96 20.35 15.02 22.71 21.37 25.17 51.42 63.97 65.16 58.35 49.21 44.82 52.05 39.95
R&D 3,836 3,793 4,332 4,701 5,429 5,931 6,528 7,031 7,222 7,454 7,607 7,795 8,844 10,075 11,281 11,523 11,579 11,816 12,461 13,803
Change (%) -1.12 14.21 8.52 15.49 9.25 10.07 7.71 2.72 3.21 2.05 2.47 13.46 13.92 11.97 2.15 0.49 2.05 5.46 10.77
% of Revenue 59.95 42.90 48.75 49.75 67.96 33.49 37.04 41.25 31.73 47.88 49.42 51.09 71.31 78.92 68.64 49.37 39.55 40.98 40.37 44.23
OpEx 7,750 7,988 8,826 9,308 10,143 10,802 11,682 12,091 12,243 12,757 12,339 12,810 16,967 23,165 27,945 33,225 30,580 35,459 35,408 36,935
Change (%) 3.07 10.49 5.46 8.97 6.50 8.15 3.50 1.26 4.20 -3.28 3.82 32.45 36.53 20.63 18.89 -7.96 15.95 -0.14 4.31
% of Revenue 121.11 90.34 99.31 98.51 126.96 60.99 66.28 70.93 53.78 81.94 80.16 83.96 136.81 181.46 170.04 142.35 104.46 122.97 114.71 118.35
Operating Income -1,351 854 61 141 -2,154 6,910 5,942 4,955 10,520 2,812 3,054 2,448 -4,565 -10,399 -11,511 -9,885 -1,305 -6,624 -4,540 -5,726
Change (%) -163.21 -92.86 131.15 -1,627.66 -420.80 -14.01 -16.61 112.31 -73.27 8.61 -19.84 -286.48 127.80 10.69 -14.13 -86.80 407.59 -31.46 26.12
% of Revenue -21.11 9.66 0.69 1.49 -26.96 39.01 33.72 29.07 46.22 18.06 19.84 16.04 -36.81 -81.46 -70.04 -42.35 -4.46 -22.97 -14.71 -18.35
Interest Expense -443 -207 -113 -250 -464 -518 -651 -674 -316 -673 -656 -688 -1,013 -787 -800 -795 -2,209 -769 -847 -1,892
Change (%) -53.27 -45.41 121.24 85.60 11.64 25.68 3.53 -53.12 112.97 -2.53 4.88 47.24 -22.31 1.65 -0.62 177.86 -65.19 10.14 123.38
% of Revenue -6.92 -2.34 -1.27 -2.65 -5.81 -2.92 -3.69 -3.95 -1.39 -4.32 -4.26 -4.51 -8.17 -6.16 -4.87 -3.41 -7.55 -2.67 -2.74 -6.06
Net Income -1,671 1,479 1,072 1,299 1,296 1,017 100 -224 -383 382 1,050 1,860 -3,378 -7,193 -9,072 -9,836 -3,711 -4,838 -2,317 -3,272
Change (%) -188.51 -27.52 21.18 -0.23 -21.53 -90.17 -324.00 70.98 -199.74 174.87 77.14 -281.61 112.94 26.12 8.42 -62.27 30.37 -52.11 41.22
% of Revenue -26.11 16.73 12.06 13.75 16.22 5.74 0.57 -1.31 -1.68 2.45 6.82 12.19 -27.24 -56.34 -55.20 -42.14 -12.68 -16.78 -7.51 -10.48

Source: Capital IQ

Other Listings
JP:4565 JP¥ 990.00
DE:JSS € 5.60
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista